Release date: 30 January 2020
Promoter – Financial Intermediary
ITM ISOTOPEN TECHNOLOGIEN MUENCHEN AGLocation
Description
The project concerns RDI investments of a proprietary portfolio of nuclear medicine solutions for diagnosis and treatment of cancer, addressing a range of indications such as neuroendocrine tumours, bone metastases or prostate cancers. This portfolio includes new radionuclides and radiopharmaceuticals in various stages of clinical development, covering discovery, pre-clinical and clinical (Phase I-III) and technical validation phases.
Objectives
The project falls within the scope of the Horizon 2020 programme Societal Challenges (Health, Demographic Change and Wellbeing).
Sector(s)
- Services - Professional, scientific and technical activities
Proposed EIB finance (Approximate amount)
EUR 40 million
Total cost (Approximate amount)
EUR 92 million
Environmental aspects
The project mainly concerns investments in R&D (process development, clinical studies, regulatory development/production capacity, etc.) that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an EIA under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Procurement
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.
Status
Signed - 20/12/2019
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).